Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Germany: Drug Spending Crack Down Could Mean Tougher Reference Pricing Measures

Executive Summary

Pricing reforms in Germany could have a ripple effect elsewhere as other countries look for inspiration on how to reign in pharmaceutical spending.

You may also be interested in...



Germany’s New Government Will Maintain Price Freeze And Slash Free Pricing Period

Big changes are in store on the drug pricing front in Germany. Further reforms could depend on who is appointed health minister.

Added Benefit For Orphans Is ‘Fictitious’ Says German HTA Body

Industry has warned that reforming the system for evaluating orphan drugs could have serious consequences for patient access.

COVID-19 Pandemic Means Another Delay For Canadian Pricing Reforms

Industry has have welcomed another delay to the implementation of drug pricing reforms that aim to lower Canadian drugs prices.

Topics

UsernamePublicRestriction

Register

PS145466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel